MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with
Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
On June 26, 2013, MorphoSys and Celgene Corporation announced an agreement to
jointly develop MOR202 globally and to co-promote MOR202 in Europe. MOR202 is a
fully human monoclonal antibody targeting CD38 to treat patients with multiple
myeloma (MM) and certain leukemias.
Today at 4:00 p.m. CET (10:00am EST, 03:00pm BST), the Management Board of
MorphoSys AG will host a public conference call and webcast to present more
information on the transaction.
Dial-in number for the Conference Call (listen-only):
Germany: +49 89 2444 32975
For U.K. residents: +44 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation through
a simultaneous slide presentation online at http://www.morphosys.com.
An audio replay and manuscripts of the conference will be available on
www.morphosys.com/conference-calls in due course.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Conference Call Alert (PDF):
http://hugin.info/130295/R/1712349/568251.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1712349]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="American Graphite Technologies Inc. Announces Independent 3rd Party Graphene/Bucky Paper Test Results From CTI Nanotechnologies LLCDatum: 27.06.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 273732
Anzahl Zeichen: 4404
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple Myeloma"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
